This protocol compares daily dapsone to daily atovaquone in an effort to prevent PCP in HIV infected patients with CD4 counts less than or equal to 200/20% of whom are unable to tolerate Bachrim. The purpose of this study is to determine the relative roles of these prophylaxes in this setting.
Showing the most recent 10 out of 423 publications